Article
Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer.
Breast cancer research and treatment - 1 Sept 2010
Reding Kerryn W, Bernstein Jonine L, Langholz Bryan M, Bernstein Leslie, Haile Robert W, Begg Colin B, Lynch Charles F, Concannon Patrick, Borg Ake, Teraoka Sharon N, Törngren Therese, Diep Anh, Xue Shanyan, Bertelsen Lisbeth, Liang Xiaolin, Reiner Anne S, Capanu Marinela, Malone Kathleen E
Abstract excerpt
Given the greatly elevated risks of contralateral breast cancer (CBC) observed in breast cancer patients who carry mutations in BRCA1 and BRCA2, it is critical to determine the effectiveness of standard adjuvant therapies in preventing CBC in mutation carriers. The WECARE study is a matched, case-control study of 708 women with CBC as cases and 1,399 women with unilateral breast cancer (UBC) as controls,...
Topics
- Adult
- Antineoplastic Combined Chemotherapy Protocols
- BRCA1 Protein
- BRCA2 Protein
- Breast Neoplasms
- Case-Control Studies
- Chemotherapy, Adjuvant
- DNA Mutational Analysis